Cutler Group LP Immunic, Inc. Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	SELL	$1.35 - $2.87 $810 - $1,722	-600 Reduced 30.0%	1,400 $2,000
Q4 2022 Feb 07, 2023	BUY	$1.13 - $10.8 $2,033 - $19,440	1,800 Added 900.0%	2,000 $2,000
Q3 2022 Oct 25, 2022	BUY	$3.0 - $5.49 $300 - $549	100 Added 100.0%	200 $0
Q2 2022 Aug 04, 2022	SELL	$3.13 - $12.25 $1,943 - $7,607	-621 Reduced 86.13%	100 $0
Q1 2022 Apr 14, 2022	BUY	$9.54 - $14.26 $1,154 - $1,725	121 Added 20.17%	721 $8,000
Q4 2021 Jan 18, 2022	BUY	$7.34 - $10.25 $2,936 - $4,100	400 Added 200.0%	600 $5,000
Q3 2021 Oct 26, 2021	SELL	$8.05 - $13.29 $805 - $1,329	-100 Reduced 33.33%	200 $1,000
Q2 2021 Jul 19, 2021	SELL	$11.76 - $16.85 $47 - $67	-4 Reduced 1.32%	300 $3,000
Q1 2021 Apr 26, 2021	SELL	$14.21 - $25.3 $4,177 - $7,438	-294 Reduced 49.16%	304 $4,000
Q4 2020 Jan 21, 2021	BUY	$14.8 - $20.37 $5,150 - $7,088	348 Added 139.2%	598 $9,000
Q3 2020 Oct 27, 2020	BUY	$11.74 - $22.0 $2,935 - $5,500	250 New	250 $4,000

56.3M

100

350K

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $29.3M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.